Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of ...

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like ...